The incidence of preterm birth in the US continues to rise. Infants born before 28 weeks gestation are particularly vulnerable to CNS injury, including cerebral palsy, epilepsy, cognitive and behavioral abnormalities. These deficits impart a significant burden to the children, their families, and society. Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival.

Object. Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival.

Methods. Transient systemic hypoxia-ischemia (TSHI) on embryonic Day 18 in rats mimics human early-third-trimester placental insufficiency. This model was used to test the authors’ hypothesis using a novel clinically relevant paradigm of prenatal injury on embryonic Day 18, neonatal systemic rhEPO administration initiated 4 days after injury on postnatal Day 1, and histological, biochemical, and functional analyses in neonatal, juvenile, and adult rats.

Results. The results showed that prenatal TSHI upregulates brain EPO receptors, but not EPO ligand. Sustained EPO receptor upregulation was pronounced on oligodendroglial lineage cells and neurons, neural cell populations particularly prone to loss from CNS injury due to preterm birth. Postnatal rhEPO administration after prenatal TSHI minimized histological damage and rescued oligodendrocytes and γ-aminobutyric acidergic interneurons. Myelin basic protein expression in adult rats after insult was reduced compared with sham controls, but could be restored to near normal levels by neonatal rhEPO treatment. Erythropoietin-treated TSHI rats performed significantly better than their saline-treated peers as adults in motor skills tests, and showed significant seizure threshold restoration using a pentylentetrazole increasing-dose paradigm.

Conclusions. These data demonstrate that neonatal rhEPO administration in a novel clinically relevant paradigm initiated 4 days after a global prenatal hypoxic-ischemic insult in rats rescues neural cells, and induces lasting histological and functional improvement in adult rats. (DOI: 10.3171/2010.5.PEDS1032)

Key Words • cerebral palsy • epilepsy • oligodendrocyte • erythropoietin receptor • γ-aminobutyric acid • preterm brain injury
Perinatal erythropoietin neuroprotection

Signaling from the pleiotropic cytokine EPO through its cognate receptor EPOR is essential for CNS development. Prenatal developmentally coordinated spatiotemporal expression of both EPO ligand and receptor regulates local neuronal survival after neurogenesis, while the expression of EPO and EPOR dramatically diminishes postnatally. Binding of EPO to EPOR activates cell survival pathways, while receptors without bound EPO ligand appear to promote cell death. After injury to the mature CNS, both EPO and EPOR expression are upregulated as part of an endogenous neuroprotective mechanism. In the developing brain, however, injuries appear to induce elevated EPOR expression without an apparent concomitant increase in EPO expression. This disruption of the coordinated expression of ligand and receptor potentially leaves neural cells vulnerable to cell death. Recombinant human EPO administration has been shown to improve markers of brain damage after multiple types of neonatal and adult CNS insults when initiated prior to or within 24 hours of the insult, but has never been investigated with a long, clinically relevant interval between the insult and treatment. We propose that the sustained mismatch of EPO ligand and receptor levels after prenatal injury creates a potential therapeutic window for treatment initiated well after the insult occurs.

Third trimester placental insufficiency injures the developing brain, including inducing persistent loss of oligodendroglial lineage cells and GABAergic neurons. To investigate whether a potential postnatal therapeutic window exists after a prenatal global hypoxic-ischemic insult, rhEPO treatment was initiated in newborn animals after embryonic Day 18 transient uterine artery occlusion. This model induces persistent and pervasive loss of oligodendrocytes and neurons with functional deficits in adult rats, similar to other rodent models, and consistent with findings observed in human infants with brain injury from early preterm birth. After prenatal TSHI on embryonic Day 18, EPOR transcription and expression is markedly upregulated on neural cells, whereas EPO ligand transcription fails to rise, suggesting a loss of the coordinated developmental regulation of ligand and receptor essential for cell survival. We propose that injury to the prenatal developing brain causes sustained elevated neural cell EPOR expression, and that addition of rhEPO can rescue these EPOR-positive neural cells from death. Prenatal TSHI also impairs motor performance and lowers the seizure threshold in adult rats, and these deficits improve after neonatal neuroprotective doses of rhEPO. Neonatal rhEPO after prenatal injury improves neural cell survival and functional outcomes in postinsult adult animals with restoration of myelin production, motor skills, and seizure threshold.

Methods

Prenatal TSHI Insult

Approval to perform the study was obtained from the Institutional Animal Care and Use Committee at Case Western Reserve University School of Medicine. Timed-pregnant Sprague-Dawley rats were purchased (Zivic Laboratories), and TSHI was induced on embryonic Day 18. Briefly, a laparotomy was performed on the rats under isoflurane inhalation anesthesia, uterine arteries were occluded for 60 minutes, and the laparotomy was closed. For sham control animals the laparotomy was performed without arterial occlusion. Pups were born at term (embryonic Day 22), except for those pups whose brains were harvested at embryonic Day 19. Fetal loss after the insult was 23%, and 0% for sham controls. Rats were killed and perfused with 4% paraformaldehyde, or tissue was collected and frozen at −80°C for biochemical analyses. All samples were coded for the performance of the histological and biochemical analyses. The experimental paradigm is illustrated in Fig. 1. Except where noted, consistent areas of frontal lobe were analyzed with anatomical and biochemical techniques to minimize potential differences due to regional variation.

Postnatal rhEPO Treatment

Recombinant human EPO (tissue culture grade 287-TC, R&D Systems) was administered to rat pups by intraperitoneal injection beginning on postnatal Day 1, with a portion of the pups in each litter receiving rhEPO, and an equivalent portion receiving saline. Each pup was tagged for future identification. Three rhEPO dosing regimens were used: low (500 IU/kg for 1 day), moderate (1000 IU/kg for 3 days), and high (2000 IU/kg for 5 days; Fig. 1). The dosing interval of 1 day was chosen based on pharmacokinetic studies. The low dose approximates the anemia dose currently used in human infants, and the moderate and high doses are neuroprotective doses previously used in young and mature rodents prior to or simultaneous with injury. All dose regimens were used for functional tests in juvenile rats. The moderate dose regimen was used to assess histological changes at postnatal Days 5 and 9. Only the high-dose regimen was used for adult outcome studies, as the objective was to determine whether neonatal rhEPO administered through a critical developmental window could affect the mature CNS after prenatal injury.

Erythropoietin and EPOR Real-Time RT-PCR

Total RNA was extracted from frontal lobe samples. For 18S rRNA positive controls, RNA was extracted from the samples, and for EPO pathway positive controls, kidney samples were used. Complementary DNA was synthesized from 2.5 μg of total RNA. Primers for EPO (GenBank No. EPO: NM_007942), EPOR (GenBank No. EPOR: NM_017002.2) and 18S rRNA were purchased (Integrated DNA Technologies). Real-time PCR was performed and analyzed using the BioRad iQ5 system (Bio-Rad). The comparative cycle threshold (Ct) method was used. Standard curves were generated using a 2-fold dilution of the cDNA sample as the PCR template. The transcript level in each sample was normalized to the 18S mRNA (an endogenous reference gene used as an internal control) within that sample, named ΔCt. At least 3 independent experiments were performed and all reactions were performed with technical triplicates. The ratio of EPO ΔCt to EPOR ΔCt shows the relative discrepancy
between EPO ligand and receptor transcript levels, with a higher ratio indicating less EPO mRNA present compared with EPOR mRNA.

**In Situ Hybridization**

An EPO receptor probe was made using complete rat EPOR cDNA as a template. The sequence of antisense primer was GTA ATA CGA CTC ACT ATA GGG AGA GGG GCA GGA AGA TGT TT and the sense primer was GAA TTA ACC CTC ACT AAA GGG TGA GTG TGT CCTGAGCAA CC. Polymerase chain reaction was used to generate EPOR primers with T7 and T3 promoter sequences. The PCR product was purified with the MinElute Gel Extraction Kit (Qiagen). Erythropoietin receptor RNA probes were synthesized using Digoxigenin Oligonucleotide Tailing Kit (Roche). Transcription reaction with T7 RNA polymerase (Digoxigenin RNA Labeling Kit, Roche) synthesized the antisense probe and the transcription with T3 RNA polymerase synthesized the sense probe. Probes were purified with ethanol and tested on agarose gel to confirm the appropriate band. Probes were aliquoted and stored at ~80°C.

**Erythropoietin ELISA**

Frontal lobe specimens were rinsed with phosphate-buffered saline, weighed, homogenized by ultrasonication in phosphate-buffered saline with protease inhibitor cocktail (Sigma), snap frozen, and stored at ~80°C. Serum samples were also snap frozen after collection. Enzyme-linked immunosorbent assay was performed per the manufacturer’s directions using commercial rat and human EPO kits (R&D Systems). After 2 freeze-thaw cycles, homogenates were centrifuged at 8000 rpm for 5 minutes. Supernatants were collected, protein concentration was measured, and ELISA was performed in triplicate. Intensity was measured at 450 nm using a Kinetic microplate reader (Molecular Devices). At least 2 complete experiments were performed.

**Western Blots**

Frontal lobe samples were weighed, lysed in lysis buffer, centrifuged, pellet resuspended, and protein-concentration determined (Pierce). Equal amounts of protein were applied to 10% sodium dodecyl sulfate-polyacrylamide gels, and electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore). The membrane...
was incubated with EPOR or mouse anti-MBP antibody (Sternberg Monoclonals). Visualization was performed with horseradish peroxidase-conjugated goat anti–rabbit antibody (MBIImedicals), and enhanced chemiluminescence (Pierce). After EPOR or MBP analysis, blots were stripped and reprobed with anti–β-actin (Santa Cruz Biotechnology) antibodies. Band intensity was quantified using a densitometer (Biorad). Three complete experiments were performed.

**Immunohistochemical Analysis**

Coronal sections (50 μm) were cut from anterior to posterior beginning at the ventral hippocampal commissure (bregma −1.4 mm) and ending at the anterior temporal horn (bregma −3.6 mm). Every fourth section was immunolabeled for a specific antigen to avoid any possibility of overlap from using adjacent sections. Sections were incubated with block, primary antibody, appropriate secondary antibody, Vectastain (Vector Laboratories), and diaminobenzidine, and dehydrated and mounted. Images were captured using a Leica microscope and Open Lab 3.17 (Improvision, PerkinElmer). For neonatal pups, images and labeled cell counts were obtained bilaterally at the level of the corpus callosum genu from the following areas: cleaved caspase-3 (Cell Signaling) at postnatal Days 5 and 9 in periventricular white matter; GAD-67 (Chemicon) at postnatal Day 9 in the cingulate region; O4-immunopositive oligodendrocytes44 at postnatal Day 9 in periventricular white matter and corpus callosum; and EPO (SC-7956, Santa Cruz Biotechnology) and EPOR (AF1390, R&D Systems; M-20, Santa Cruz Biotechnology) at postnatal Days 2, 5, and 9 in the subplate region superolateral to the lateral ventricle/hippocampus, and periventricular white matter. Both commercial EPOR antibodies produced the same pattern of immunolabeling. Sections incubated without primary antibodies were used to test the specificity of both EPOR antibodies. For GAD-67 or parvalbumin (Sigma)–labeled neurons at postnatal Day 24 and in adults, bilateral images were obtained from each section of the deep parietal trunk area (bregma −2.3 mm to −3 mm). To optimize comparisons between groups and minimize bias, nuclei of immunolabeled cells were counted in regions of interest from 3–5 fields (magnification 10) obtained from ≤3 sections per rat. For EPOR and O4 double labeling in vivo, frozen floating sections were cut at 40 μm, blocked in 10% fetal calf serum, incubated sequentially with O4, fluorochrome Alexa564, anti–EPOR (R&D Systems), rabbit anti–goat immunoglobulin G–conjugated biotin antibodies, and streptavidin-Cy2, and mounted. Images were obtained using a Zeiss confocal microscope. For TUNEL staining to corroborate the activated caspase-3 immunohistochemistry at postnatal Day 9, perfused brains were immersed in 30% sucrose, coronal frozen sections were prepared, and the TUNEL reaction was performed using a commercial kit (Roche). Rats were obtained for each group from 3 separate litters.

**Cell Culture**

Mixed cerebral single-cell suspensions were plated at 50,000 cells/coverslip on poly-L-lysine-coated coverslips, and incubated overnight in supportive media (N2 supplement, 1% fetal bovine serum, and platelet-derived growth factor A (10 ng/ml)). The next day cells were incubated with monoclonal antibody for A2B5-immunoreactive oligodendrocyte precursors, O4-immunoreactive oligodendrocytes, and O1-immunoreactive mature oligodendrocytes; astrocytes (GFAP, Dako), neurons (β-tubulin, T8660 Sigma), and microglia (ED1 [CD68] no. 1435, Chemicon), incubated with rhodamine-conjugated secondary antibodies, anti–EPOR antibodies (R&D Systems), biotin-conjugated rabbit anti–goat antibodies, and Cy2-conjugated anti–rabbit tertiary antibodies. Nuclei were labeled with DAPI (Invitrogen). Controls without primary antibodies were investigated to confirm the specificity of the immunolabeling. Immunolabeling of cells (EPOR, cell type marker, DAPI) was photographed on a Leica microscope using software with consistent exposure settings. Erythropoietin receptor labeling on individual immunolabeled cells with round healthy DAPI-immunopositive nuclei was graded by an observer blinded to insult status semiquantitatively as 0 (no EPOR detected), 1 (faint EPOR immunolabeling), or 2 (strong EPOR-immunopositive) for >50 cells per cell type per experiment, and 3 complete experiments were performed.

**Motor Skills**

The global insult produced by the prenatal TSHI results in bilateral damage, and consequently most skills tests designed for evaluation after a focal unilateral insult such as unilateral carotid occlusion are unsuitable. For motor tests, all groups of rats were tested on the same day under the same conditions. The bar hold test was used for juvenile rats, and the stride length44 and irregular horizontal ladder performance45 tests were used for adult rats (3–4 months) with the sex also recorded. For the bar hold test, the length of time each rat was able to support itself from a 12-mm diameter bar above a padded surface was recorded for 3 consecutive trials. The average ± SEM individual trial time for each group was calculated. For stride length, adult rats had nontoxic paint applied to their feet, and each rat ran once down a strip of paper covered by an open mesh wire tunnel into a home cage. The maximal unilateral stride length was measured for 5 steps for each rat, and the mean ± SEM for each group obtained.

For the irregular horizontal ladder performance test, a 1-m-long ladder with 27 irregularly spaced rungs, each 8-mm in diameter, was used. The ladder was suspended 15 cm above a mirrored surface to facilitate visualizing the rats’ feet. Rats ran toward a home cage and no other inducements were used. The day before testing, each rat had 1 trial in the reverse direction to habituate it to the apparatus. On the day of testing, rats were videotaped as they crossed the ladder. The videotape was reviewed by an observer blinded to the insult and treatment status to assess the time to cross the ladder, the number of times each foot stepped correctly on a rung (step), or dropped below a rung (error), similar to a score of 2 in the scale developed by Metz and Whishaw. The number of times both feet fell off simultaneously (drop) was also recorded. The mean number of rear leg errors and total errors per group was calculated. Rats for each group were obtained from at least 2 litters.
Pentylenetetrazole Seizure Threshold

An escalating dose paradigm with PTZ was used to define the average dose necessary to induce seizures, or seizure threshold. Each rat was uniquely marked, sex was recorded, and rats were weighed on each testing day. The first day rats were administered 20 mg/kg of PTZ intraperitoneally, and every third day afterward they received a PTZ dose increased by 10 mg/kg. The latency to the 3 seizure grades was recorded with a maximal observation period of 30 minutes. Grade I was head jerk only, Grade II was head-to-tail jerk, and Grade III was a generalized tonic-clonic seizure.15 A rat was removed from testing once it experienced a Grade III seizure. If a rat did not have a Grade III seizure, it was administered the increased dose on the next testing day. Rats for each group were obtained from at least 2 litters.

Quantification and Statistics

All observations and labeled cell counts were performed by an observer blinded to the insult and treatment status. Results were collected from rats from at least 2 litters for each study, and at least 3 independent experiments were performed (the exact number of experiments is noted in the figure legends), except for hematocrits (2 experiments). Results are expressed as the mean ± SEM. Statistical analyses were performed using SPSS version 11.5 (SPSS Inc.). Differences between the means for insult and sham control pups were compared using the Student 2-tailed t-test. Differences in the means between the multiple treatment groups were compared using 2-way ANOVA, with Bonferroni correction for post hoc analysis of ≥ 3 groups. Statistical significance was set at p ≤ 0.05.

Results

Prenatal Injury, EPO Ligand, and Receptor Transcription and Expression

Real-time RT-PCR with the comparative Ct technique was performed on perinatal frontal lobe samples to determine mRNA transcription, with ribosomal 18S used as an endogenous control in each sample (\( \Delta \text{Ct} = \text{Ct}(\text{target gene}) – \text{Ct}(18S) \)). For the EPO ligand more cycles were required to reach the fixed threshold in both sham controls and those animals with brain insult at postnatal Day 5, compared with postnatal Days 0 and 2 (4–7 cycles; \( p < 0.01 \), 2-way ANOVA), consistent with the postnatal downregulation of EPO signaling (Fig. 2a). No significant differences in EPO transcripts were detected between control and insult animals at any age. While EPOR transcript levels were relatively stable in sham controls from embryonic Day 19 to postnatal Day 5 (Fig. 2b), the embryonic Day 18 TSHI insult induced a marked upregulation of EPOR transcription on embryonic Day 19 (\( n = 9 \)) compared with sham controls (\( n = 7; p = 0.04 \), 2-tailed t-test); that is, only approximately 10 cycles were required to reach the fixed threshold after the insult, while approximately 12.5 cycles were required in sham controls to reach the same threshold. The ratio of EPO ligand and receptor mRNA transcript levels in sham controls illustrates the gradual decrease in rate-limiting EPO ligand relative to EPOR transcripts during the perinatal period (Fig. 2c). Because a higher cycle threshold (\( \Delta \text{Ct} \)) reflects the presence of fewer target gene mRNA transcripts, a higher EPOA/C/EPOR/Ct ratio means a greater mismatch is likely with less EPO ligand mRNA present compared with receptor mRNA. After TSHI on embryonic Day 18, the insult ligand/receptor \( \Delta \text{Ct} \) ratio is about 30% higher on embryonic Day 19, indicating disruption of the developmentally coordinated regulation of ligand and receptor transcription. The ratio returns to the control level by postnatal Day 5. In situ hybridization performed on embryonic Day 19 localized the sites of increased EPOR mRNA in the cortex, subplate, and white matter after the TSHI on embryonic Day 18 (Fig. 2d). The increase in EPOR mRNA without concomitant rise in EPO ligand transcripts increases the discrepancy between ligand and receptor levels, and suggests that the potential response to rhEPO may be extended throughout a relatively long therapeutic window after the insult in the damaged developing brain.

Protein levels of EPO ligand and receptor followed similar trends to mRNA. A gradual decrease in EPO ligand was found in sham controls from embryonic Day 19 (\( n = 4 \)) through postnatal Day 5 using ELISA (\( n = 8 \); \( p = 0.003 \), 2-way ANOVA; Fig. 2e), and this was not altered by injury on embryonic Day 18. In contrast to the lack of change in ligand levels after injury, frontal lobe Western blots showed that embryonic Day 18 TSHI induces an increase in EPOR expression at postnatal Day 0, which is sustained through postnatal Day 5 (Fig. 2f). Quantification of Western blots showed an increase in EPOR expression after prenatal insult at postnatal Days 0 (\( n = 5 \)) and 5 (\( n = 10 \)), compared with sham controls (postnatal Day 0: \( n = 7; p = 0.037 \), t-test; postnatal Day 5: \( n = 10; p = 0.03 \); Fig. 2g). Ligand and receptor expression was also assayed using immunohistochemistry. No significant difference was observed in the EPO ligand between postnatal Days 2 and 9 in sham controls or after embryonic Day 18 in the TSHI group (Fig. 3a). Unlike the lack of change in EPO ligand expression after injury, increased cerebral neural cell EPOR expression was observed diffusely in both the white and gray matter from postnatal Day 2 through postnatal Day 9, up to 13 days after the embryonic Day 18 insult (Fig. 3b), and in contrast to the relative progressive decrease in EPOR expression observed in sham controls during the same interval. Detailed examination of EPO ligand expression at postnatal Day 5 in the subplate and white matter did not reveal obvious differences between sham control and insult brains (Fig. 3c). Although fewer subplate cells were present at postnatal Day 5 after TSHI (control animals: 316 ± 27 cells/mm²; insult animals: 251 ± 13 cells/mm²; \( n = 3; p < 0.01 \)), the percentage of postnatal Day 5 subplate cells immunolabeled by EPO antibodies was similar in control and insult rats (61 ± 4%). In contrast to the apparently stable EPO expression, increased EPOR expression was present in cortical cells with neuronal morphology in all cortical layers, but the increase was most prominent and persistent in the subplate (Fig. 3d). At postnatal Day 5 the proportion of subplate cells labeled with anti-EPOR antibodies was 72 ± 8% (\( n = 3 \}; EPOR-immunopositive: 191 ± 18 cells/mm²; total: 265 ± 26 cells/mm²) after embryonic
Day 18 TSHI, compared with 53 ± 9% in sham controls (n = 3; EPOR-immunopositive: 153 ± 27 cells/mm²; total: 289 ± 21 cells/mm²; p = 0.0001, t-test). Similarly, the number of EPOR-immunopositive cells in the white matter at postnatal Day 5 increased after the insult (n = 4; 250 ± 23 cells/mm²), compared with sham controls (n = 4; 171 ± 22 cells/mm²; p = 0.001). After prenatal TSHI, cerebral neural cell EPOR transcription and expression are increased in the developing CNS in both gray and white matter through postnatal Day 9, almost 2 weeks after the initial insult, whereas the insult does not markedly alter EPO ligand levels during the same period. The excess expression of EPOR after TSHI without a concomitant increase in EPO suggests that the mismatch between EPO ligand and receptor levels occurs after prenatal TSHI.

Erythropoietin Receptor Presence on Immature Oligodendrocytes and Neurons

To determine the specific CNS cell types that expressed EPOR, double-labeling for EPOR and neural cells...
was performed. Erythropoietin receptors were present on O4-immunopositive oligodendrocytes in the white matter in sham controls in vivo (Fig. 4a). To allow more detailed evaluation of EPOR expression after prenatal TSHI on different neuronal and glial cell types, immunocytochemistry was performed on postnatal Day 2 equivalent (postnatal Day 1 + 1 day in vitro) cells. In sham controls, EPOR expression was found on all 3 stages of oligodendroglial cells examined. Indeed, 45 ± 3% of sham control O4-immunopositive immature oligodendrocytes had EPOR labeling present primarily on the cell body and proximal processes (Fig. 4b). In cultures derived from ischemic animals, the proportion of O4-immunopositive cells with EPOR expression increased 2-fold to 85 ± 5%. The intensity of EPOR labeling on each cell was estimated semiquantitatively (0 = none, 1 = faint, 2 = bright). The average intensity of EPOR expression per cell on O4-immunopositive cells increased markedly after embryonic Day 18 TSHI (n = 100) compared with sham controls (n = 86; p = 0.0001, t-test; Fig. 4c). The increase in EPOR on A2B5-immunopositive
oligodendrocyte precursor cells after injury (99 cells) was also significant (116 controls; p = 0.02). No significant difference in EPOR expression was observed on mature O1-immunopositive oligodendrocytes (29 controls, 49 insult). Elevated EPOR expression was also found on other cell types in the brain after prenatal TSHI, including β-tubulin-positive neurons, GFAP-positive astrocytes, and ED1-positive microglia. After the embryonic Day 18 insult, the average intensity of EPOR expression per cell was increased compared with sham control cells (p < 0.02, **p < 0.0001). The average intensity of EPOR expression per cell after the embryonic Day 18 insult was also increased in vitro at postnatal Day 2 on neurons, astrocytes, and microglia (p < 0.0001, **p = 0.0003).
Exogenous EPO and Histological Signs of Damage in Vivo

To investigate the impact of neonatal rhEPO after TSHI on embryonic Day 18, 3 dosing regimens were used: low (500 IU/kg on postnatal Day 1), moderate (1000 IU/kg on postnatal Days 1–3), and high (2000 IU/kg on postnatal Days 1–5). The 3 dosing regimens were designed to identify an effective dose and define a therapeutic window, given the prolonged period of increased EPOR expression observed after the prenatal injury. Human EPO levels in rat serum were elevated after 2 days of systemic rhEPO administration, while human EPO levels were near zero without rhEPO administration (Fig. 5a).

This suggests that intraperitoneal injection of rhEPO is readily absorbed and distributed within the vasculature. Hematocrits were measured on postnatal Day 5 after the different dosing regimens to assess the impact of systemic rhEPO administration. The TSHI on embryonic Day 18 lowered the postnatal Day 5 hematocrit of saline-treated TSHI pups (n = 6) compared with sham controls (n = 10; p = 0.003, 2-tailed t-test; Fig. 5b). The low (n = 5) and moderate (n = 5) dosing regimens did not alter the hematocrit, but the high-dose regimen increased the postnatal Day 5 hematocrit by 12% in both control and insult pups (n = 5; p < 0.001, 2-way ANOVA). The mild increase...
Perinatal erythropoietin neuroprotection

in hematocrit induced by the high-dose rhEPO regimen counterbalanced the injury-induced decrease, with the end result that the hematocrit of high-dose rhEPO-treated insult pups at postnatal Day 5 did not differ from the normal hematocrit of saline-treated sham control pups.

Transient systemic hypoxia-ischemia on embryonic Day 18 causes increased cleaved caspase-3 expression, a marker of cell death, in white matter that persists for 2 weeks after the prenatal insult. To determine whether rhEPO treatment altered caspase-3 activation, the moderate rhEPO dosing regimen was administered (1000 U/kg on postnatal Days 1–3). Neonatal rhEPO markedly diminished cleaved caspase-3 expression in postinsult rat white matter at postnatal Day 9 (Figs. 5c and d) and postnatal Day 9 (Fig. 5d) to levels similar to sham controls, while saline showed no effect (n = 3–6; p < 0.0001, 2-way ANOVA). The lack of cell death at postnatal Day 9 was confirmed with TUNEL labeling (data not shown). In this model of prenatal TSHI, postnatal rhEPO administration initiated 4 days after the prenatal insult markedly reduced markers of cell death through postnatal Day 9, almost 2 weeks after the initial insult.

Presence of Neural Cells With Neonatal rhEPO After Prenatal TSHI

Significantly fewer O4-immunopositive oligodendrocytes were found in the periventricular white matter at postnatal Day 9 in saline-treated insult pups, compared with sham controls (n = 3–4; p < 0.0001; Fig. 6a and b). Neonatal rhEPO after prenatal TSHI restored the number of O4-immunopositive cells to near baseline (p < 0.0001; 2-way ANOVA). To determine whether myelin formation was influenced by neonatal rhEPO treatment, MBP expression in postnatal Day 24 and adult white matter was analyzed by Western blots (Fig. 6c and d). Less MBP was present at both ages in postinsult rats compared with sham controls (n = 4–6, adult; p = 0.005), and MBP levels were increased in EPO-treated insult animals (2000 IU/kg for 5 days) compared with saline-treated animals (adult: p = 0.002, 2-way ANOVA), suggesting that rhEPO after prenatal TSHI both restores oligodendrocyte numbers in the developing brain, and produces sustained improvement in adult myelination.

The impact of neonatal rhEPO treatment on GABAergic cortical neurons was assayed, as perinatal brain damage from prematurity results in loss of GABAergic neurons in humans and rodents. In rhEPO-treated (1000 IU/kg for 3 days) postinsult rats, significantly more GAD-67-immunopositive neurons were present in the cingulate gyrus at postnatal Day 9 compared with saline-treated postinsult rats (n = 4; p < 0.0001, 2-way ANOVA; Fig. 7a). At postnatal Day 9, neurons in rhEPO-treated animals also appeared to be more robust and to have longer neurites. Gammabutyric acidergic neuronal development is primarily

**Fig. 6.** Neonatal rhEPO treatment after prenatal TSHI restores oligodendrocyte development and myelin production. 

- **a:** Neonatal rhEPO treatment restores the number of O4-immunoperoxidase labeled oligodendrocyte lineage cells observed in the corpus callosum in vivo in postinsult rats at postnatal Day 9. Bar = 10 μm. OPCs = oligodendrocyte precursor cells. 
- **b:** The number of O4-immunopositive oligodendrocytes immunolabeled at postnatal Day 9 is diminished in the periventricular white matter after prenatal TSHI, compared with sham controls, and restored to control density with rhEPO (*p < 0.0001). 
- **c:** Western blot of MBP in juvenile (postnatal Day 24) periventricular white matter from saline-treated sham control and prenatal TSHI insult animals, and from EPO-treated controls and insults. 
- **d:** Relative proportion of MBP to β-actin at postnatal Day 24 and in adults shows insult animals had significantly less MBP present (*p = 0.028). Myelin production in rhEPO-treated postinsult adults was restored (**p = 0.002), and supranormal MBP production appeared in adult EPO-treated sham controls (***p = 0.001, 2-way ANOVA).
completed by 3 weeks in rats. Loss of GABAergic neurons was sustained at postnatal Day 24 in postinsult animals (n = 11) compared with sham controls (n = 10; p = 0.012; Fig. 7b), suggesting the loss of GAD-67–immunopositive cells found at postnatal Day 9 reflects a persistent loss of labeled cells, and not simply delayed appearance of this population. The loss was reversed by neonatal rhEPO (n = 6; p < 0.0001, 2-way ANOVA). Fast-spiking parvalbumin cortical interneurons comprise a GABAergic subpopulation whose function is critical for inhibitory circuit formation,11 and are lost in postmortem preterm infants with white matter loss.20 Significant loss of parvalbumin-immunopositive neurons (n = 7) was present at postnatal Day 24 after embryonic Day 18 TSHI in deep parietal cortical layers (primary somatosensory area) compared with controls (n = 5; p < 0.0001; Fig. 7c and d), a cortical region known to be affected by perinatal brain injury.48 After neonatal rhEPO (2000 IU/kg from postnatal Days 1–5) the number of neurons present after the prenatal TSHI injury (n = 5) was restored to control levels (p < 0.0001, 2-way ANOVA). The
Perinatal erythropoietin neuroprotection

loss of parvalbumin-immunopositive neurons persisted in adult insult rats (n = 5; control, n = 9; p = 0.0001), and improvement was observed after neonatal rhEPO (Fig. 7c). Together, these results show that neonatal rhEPO enhances the recovery of both GABAergic neurons and the oligodendrocyte lineage in both the developing and mature brain after a prenatal TSHI insult.

Motor Skills Improvement in rhEPO-Treated Rats After Prenatal Insult

Prenatal TSHI also induces motor deficits in adult rats that were reversed with neonatal rhEPO. At postnatal Day 15 the length of time each rat held onto a bar during individual trials was shorter after prenatal TSHI (n = 24, 8.6 ± 0.7 seconds), compared with controls (n = 19, 12.7 ± 1.6 seconds; p < 0.0001; Fig. 8a). When the postinsult rats were treated with high-dose rhEPO (2000 IU/kg for 5 days, n = 26), the rats’ individual trial times improved to near control levels (p = 0.002, 2-way ANOVA), while a single low dose of rhEPO (500 IU/kg on postnatal Day 1, n = 10) or 3 moderate doses on postnatal Days 1–3 (1000 IU/kg, n = 9) were ineffective. The bar holding test may reflect endurance as well as coordination, but the changes clearly suggest that early improvement in motor performance is achievable after a prenatal insult with neonatal rhEPO in a dose-dependent manner.

Motor skills in adult rats were assessed using stride length and the horizontal ladder test after high-dose neonatal rhEPO (2000 IU/kg from postnatal Days 1–5). Stride length was shorter in postinsult adults (n = 48) compared with sham controls (n = 49, p < 0.001). Neonatal rhEPO after a prenatal insult (n = 49) resulted in a longer mean stride length compared with saline-treated postinsult rats (p = 0.014, 2-way ANOVA; Fig. 8b). In the irregular rung horizontal ladder test, rhEPO-treated TSHI rats (n = 29) performed significantly better than their saline-treated peers (n = 28), with a lower number of rear leg (p = 0.005, 2-way ANOVA) and total errors (p = 0.006; Fig. 8c). These results suggest that TSHI-induced prenatal damage is mitigated by rhEPO given during neonatal development, allowing sustained improvement in motor function in adult rats.

Erythropoietin Treatment and Seizure Threshold After Prenatal Injury

The seizure threshold was tested in adult rats using a PTZ (GABA antagonist) dose escalation paradigm. For...
Each seizure grade from I to III, a significantly lower PTZ dose was required to induce seizures in rats after prenatal TSHI (n = 34), compared with sham controls (n = 41; Grade I: p = 0.012, Grade II: p = 0.02, Grade III: p = 0.033), indicating that the prenatal insult lowers the seizure threshold (Fig. 8d–f). The lower seizure threshold was restored following high-dose neonatal rhEPO (n = 37) to near control levels, and was significantly higher than the threshold in saline-treated postinsult animals (Grade I: p = 0.0001; Grade II: p = 0.006; Grade III: p = 0.006, 2-way ANOVA). To our knowledge, this is the first demonstration that the seizure threshold in adults after a prenatal insult can be altered by postnatal treatment with rhEPO.

Discussion
Prenatal TSHI and EPO Ligand and Receptor Expression

Coordinated EPO signaling is essential for CNS development.62 and exogenous rhEPO provides neuroprotection after a variety of insults in neonatal and mature animals.41 This study shows that prenatal TSHI reduces postnatally. A similar lack of increased EPO expression after injury has been observed in prenatal hypoxia, neonatal excitotoxic (postnatal Day 5) to near control levels, and was significantly higher than the threshold in saline-treated postinsult animals (Grade I: p = 0.0001; Grade II: p = 0.006; Grade III: p = 0.006, 2-way ANOVA). To our knowledge, this is the first demonstration that the seizure threshold in adults after a prenatal insult can be altered by postnatal treatment with rhEPO.

The enhanced neural cell survival observed after neonatal rhEPO translated into functional neurological improvement in juvenile pups in a dose-dependent manner, similar to others using rhEPO for neonatal focal stroke.52 The functional benefit for motor skills in this model with diffuse global prenatal injury from a systemic insult was similar to others using rhEPO for neonatal focal stroke.52 The impact of these cytokine interactions in the damaged developing brain requires further study.

Neonatal rhEPO Restores Neural Cell Development and Function

The mismatch between EPO ligand and receptor levels after injury suggests a mechanism for neural cell loss after injury, as well as an opportunity to optimize survival of EPOR-immunopositive cells with rhEPO. The therapeutic window for rhEPO as defined by increased EPOR availability may extend days after the insult in the damaged developing brain. Thus, to mimic a typical clinical scenario, we examined whether neonatal rhEPO treatment administered with a significant interval between the insult and treatment could reverse brain damage from a prenatal global insult and result in lasting functional improvement in the mature CNS. Neonatal rhEPO administered after prenatal TSHI reduced signs of damage, including cleaved caspase-3 activation in developing white matter after postnatal Day 9, similar to the decrease in apoptosis found in other models using prior or concurrent rhEPO treatment with injury.27,30,36 Neonatal rhEPO after prenatal injury also restored the number of O4-immunopositive oligodendrocytes present at postnatal Day 9, and MBP levels present at postnatal Day 24 and in adult rats, the first demonstration of rhEPO-induced improvement of oligodendrocyte function in adults after prenatal brain injury. Improved myelin formation was also found with rhEPO after spinal cord injury in adult rats.56 We found treatment with neonatal rhEPO also improved survival of GAD-67-positive neurons at postnatal Day 9, and both GAD-67-positive neurons and parvalbumin-positive neurons in older rats. The ability of rhEPO to reverse neuronal damage after multiple types of injury in older animals, including neonatal and adult hypoxia-ischemia, adult concussive injury, and kainate toxicity, is a well-known phenomenon.63,55 In this study, neonatal rhEPO administered after prenatal TSHI insult enhanced the survival of oligodendrocytes and neurons with sustained histological improvement in adult rats.

The enhanced neural cell survival observed after neonatal rhEPO translated into functional neurological improvement in juvenile pups in a dose-dependent manner, similar to others using rhEPO for neonatal focal stroke.27 The functional benefit for motor skills in this model with diffuse global prenatal injury from a systemic insult was sustained in adult rats after neonatal rhEPO treatment. Other studies that investigated long-term rhEPO effects in rodents after neonatal insults also found lasting improvement at 6 weeks and in adults when EPO was administered coincident with or immediately after injury.28,33,50 In our paradigm the extended interval between the embryonic Day 18 TSHI insult and postnatal rhEPO treatment may occur in isolation, and complex interactions with other cytokines are emerging. For example, EPO acts synergistically with insulin-like growth factor-1 to enhance neuronal survival.44 Tumor necrosis factor-α signaling via tumor necrosis factor receptor-1 is also essential for EPO neuroprotection in the mature brain, as EPO fails to protect brains of tumor necrosis factor receptor-1-deficient mice from middle cerebral artery stroke as it does in wild type mice.56 The impact of these cytokine interactions in the damaged developing brain requires further study.
Perinatal erythropoietin neuroprotection

more accurately reflect the likely clinical scenario for infants born very preterm in which the brain injury likely begins prenatally and is typically diagnosed postnatally.

Children with perinatal brain damage are prone to develop epilepsy.6 In a study of PTZ-induced seizures in previously healthy rats, rhEPO administered prior to PTZ challenge minimized alterations in seizure threshold.6 In this study, neonatal rhEPO elevated the adult PTZ seizure threshold back to normal levels after embryonic Day 18 TSH1, suggesting that the alterations in neuronal development and circuit formation that occur after a prenatal insult and cause epilepsy are potentially reversible. For several reasons related to the anatomical simplicity of the rat compared with humans, the impact of rhEPO in rodents may be muted compared with that possible in humans. To our knowledge this is the first study to demonstrate that a neuroprotective agent administered several days after a prenatal insult can normalize the seizure threshold in the mature brain.

Clinical Implications

Erythropoietin shows particular promise for neuroprotection after perinatal brain injury. Neuroprotective EPO doses do not cause harmful side effects when administered to neonatal rodents.33 Erythropoietin neuroprotection may be particularly useful in neonates because it could enhance oligodendroglial and neuronal maturation during a critical developmental window, decrease injury-induced inflammation, and minimize apoptosis.34 Recent initial Phase I/II studies to test the safety of neuroprotective doses in human preterm infants showed no adverse events occurred.16,22 The safety and efficacy of neuroprotective EPO dosing regimens in neonates born preterm should be specifically evaluated.

Conclusions

Using a novel, clinically relevant treatment paradigm, we found neonatal rhEPO treatment initiated 4 days after TSH1 on embryonic Day 18 resulted in histological and functional improvement in adult rats. As EPO binding of EPOR enhances neuronal and oligodendroglial survival and maturation, rhEPO has significant potential to safely improve the neurodevelopmental outcome of high-risk infants born preterm. In addition, EPO signaling will be useful for further investigation of how the developing brain undergoes repair after insults.

Disclosure

This work was supported by grants to Dr. Robinson from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, No. K08 NS46486 and R01 NS060765, and from the Rainbow Babies and Children’s Hospital Board of Trustees.

Author contributions to the study and manuscript preparation include the following. Conception and design: Robinson. Acquisition of data: Robinson, Mazur. Analysis and interpretation of data: all authors. Drafting the article: Robinson, Mazur. Critically revising the article: Robinson, Miller. Reviewed final version of the manuscript and approved it for submission: all authors. Statistical analysis: Robinson. Administrative/technical/material support: Robinson. Study supervision: Robinson.

Acknowledgments

The authors thank Anne DeChant, Stephanie Eaton, Qing Li, and Elizabeth Shick for their excellent technical assistance with the preparation of this manuscript.

References

Perinatal erythropoietin neuroprotection


Address correspondence to: Shenandoah Robinson, M.D., Pediatric Neurosurgery, B501, Rainbow Babies & Children’s Hospital, 11100 Euclid Avenue, Cleveland, Ohio 44106. email: shenandoah.robinson@UHhospitals.org.